ABBVIE INC. ABBV
$288.69
+1.84%
at last close
Market Cap$500.94 billion
P/E Ratio—
Div Yield2.40%
Volume1.93M
52-Week Range
$190.75$291.40
Analyst Ratings
- Consensus
- Buy — 19 Buy · 3 Hold · 0 Sell (22 analysts)
- Avg. Price Target
- $285.67 (-1.0% downside)
Key Stats
- Today's Range
- $286.97 – $291.40
- 50-Day Range
- $241.20 – $291.40
- 52-Week Range
- $190.75 – $291.40
- Volume
- 1.93 million shs
- Average Volume
- 4.53 million shs
- Market Cap
- $500.94 billion
- P/E Ratio
- —
- Dividend Yield
- 2.40%
Dividend
- Dividend Yield
- 2.40%
- Annual Dividend
- $6.92
- Payout Ratio
- —
- Ex-Dividend Date
- 2026-10-15
Short Interest
- Short Interest
- 0.85%
- Days to Cover
- 5.34
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Related Stocks
Compare head-to-head: ABBV vs LLY·ABBV vs JNJ·ABBV vs ABT·ABBV vs PFE
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.